Post TAVR Dialysis: a Severe Complication Less and Less Frequent

The prevalence of pre-procedural kidney failure in patients undergoing transcatheter aortic valve replacement (TAVR) can be as high as 50 – 60% (stage 3 kidney failure or worse); it has been strongly associated with acute kidney deterioration and, ultimately, an increase of post TAVR mortality.

Diálisis post TAVI, una complicación grave que se hace menos frecuente

A recent meta-analyzis of several small studies carried out in a single center, reported a dialysis need rate of 5.8% associated with a 9 fold increase in mortality. However, at the same time, the German TAVR Registry confirmed mortality increase at 30 days (not at one year).

 

So far, there were no studies assessing whether the prognosis was different for patients requiring post procedural dialysis compared to patients already presenting fatal kidney failure prior procedure.


Also Read: Incomplete Revascularization Associated to Mortality in TAVR”.


The UK TAVI Registry was established to report the outcomes of all TAVR procedures in the UK between 2007 and 2014. Data were gathered prospectively from 6464 patients at a mean follow up of 625 days. 

 

The proportion of patients that were on dialysis prior to TAVR remained constant in time, with 1.8%. However, the number of patients requiring new dialysis after procedure varied. Between 2007 and 2008, 6.1% of patients undergoing TAVR required post procedural dialysis, but in the period 2013-2014, it dropped to 2.3%.

 

The risk of new dialysis after procedure was independently associated to baseline kidney failure, ventricular dysfunction, diabetes, the use of the Edwards valve, an access other than femoral, the need of open surgery, and mild to severe residual aortic regurgitation.


Also Read: Dual APT in TAVR: Is Single Better?”


The need of dialysis after TAVR was associated to major mortality both at 30 days (HR: 6.44; CI 95%: 4.87 to 8.53) and 4 years (HR: 3.54; CI 95%: 2.99 to 4.19; p<0.001).

 

Conclusion

The proportion of patients requiring dialysis after TAVR has dropped in time, but continues to be a factor clearly associated to mortality, both at short and long term.

 

Editorial Comment

The incidence of new dialysis decreased year after year regardless patient comorbidities or procedure characteristics (at least those recorded in the database), which is why we could think operator experience plays a major role.

 

All the factors involved in post procedural kidney failure were the ones typically associated to this complication; the only exception was valve type. Actually, it is difficult to explain why after multiple adjustments the balloon expandable valve from Edwards was associated to more post procedural kidney failure and this, in turn, did not raise mortality. Perhaps, the simplest explanation is that given the positive outcomes and the ample experience operators have with this device, they might be inclined to use it in the most challenging cases, more prone to develop kidney failure.

 

Título original: Dialysis Following Transcatheter Aortic Valve Implantation, Risk Factors and Outcomes. An Analysis from the UK TAVI Registry (Transcatheter Aortic Valve Implantation) Registry.

Referencia: Charles J. Ferro et al. JAmCollCardiol Intv 2017. Article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...

J-Valve for Chronic AR: 30-Day Outcomes of Transfemoral Valve J-Valve in Chronic Aortic Regurgitation

Chronic aortic regurgitation (AR) poses a significant challenge as far as transcatheter alternatives go due to the absence of calcification and a suitable anchoring...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...